论文与基金

订阅

MedSci主页 / 所有栏目 / 论文与基金

纳米药物申请新药，将纳米载体和包埋的药物，分别进行申请行吗？

2021-09-06 MedSci原创 MedSci原创

CDE国自然
关注

国自然申请的提问与回答

更多关于国自然申请的系列课程，请下载【梅斯医学】APP观看

高博士的国自然申请课程，请点击下方图片观看：

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804631, encodeId=ef0618046310d, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jan 24 06:04:16 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075760, encodeId=e4e720e576047, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Oct 18 07:04:16 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645498, encodeId=4b1816454987b, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Jan 19 18:04:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475698, encodeId=3a8414e569881, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Sep 08 05:04:16 CST 2021, time=2021-09-08, status=1, ipAttribution=)]
    2022-01-24 DEXTER3139

    #纳米药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1804631, encodeId=ef0618046310d, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jan 24 06:04:16 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075760, encodeId=e4e720e576047, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Oct 18 07:04:16 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645498, encodeId=4b1816454987b, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Jan 19 18:04:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475698, encodeId=3a8414e569881, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Sep 08 05:04:16 CST 2021, time=2021-09-08, status=1, ipAttribution=)]
    2021-10-18 apoenzyme

    #纳米载体#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1804631, encodeId=ef0618046310d, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jan 24 06:04:16 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075760, encodeId=e4e720e576047, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Oct 18 07:04:16 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645498, encodeId=4b1816454987b, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Jan 19 18:04:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475698, encodeId=3a8414e569881, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Sep 08 05:04:16 CST 2021, time=2021-09-08, status=1, ipAttribution=)]
    2022-01-19 mei539

    #载体#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1804631, encodeId=ef0618046310d, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jan 24 06:04:16 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075760, encodeId=e4e720e576047, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Oct 18 07:04:16 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645498, encodeId=4b1816454987b, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Jan 19 18:04:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475698, encodeId=3a8414e569881, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Sep 08 05:04:16 CST 2021, time=2021-09-08, status=1, ipAttribution=)]
    2021-09-08 xugc

    #纳米药物#

    0

相关资讯

CDE发布特殊注射剂质量和疗效一致性评价技术要求（征求意见稿）

11月5日，CDE发布关于公开征求《化学药品注射剂仿制药（特殊注射剂）质量和疗效一致性评价技术要求（征求意见稿）》意见的通知。

两个大品种，首家过一致性评价

截至10月24日，CDE受理一致性评价受理号达1523个，涉及440家企业的425个品种，已过评受理号达264个（109个品种），一致性评价的热门品种扎堆严重。

CDE发布全新指导原则，近400个生物类似药面临变局？

3月17日，国家药品监督管理局药品审评中心（CDE）发布公开征求《利妥昔单抗注射液生物类似药临床指导原则（征求意见稿）》意见的通知。时隔三年，CDE再次发布单品种研发制定审评要点。上一个单品种药物为贝

CDE发布了《突破性治疗药物工作程序》和《优先审评审批工作程序》征求意见

本周五，CDE发布关于《突破性治疗药物工作程序》和《优先审评审批工作程序》征求意见的通知，对突破性治疗药物工作程序和优先审评审批工作程序做了说明。 突破性治疗药物程序、附条件批准程序、优先审评审批程序、特别审批程序是为我国鼓励创新和满足临床急需而设立的四个加快通道。其中，突破性治疗药物程序定位于药品临床试验研制阶段；优先审评审批程序定位于药品上市注册阶段。 这让人不禁联想到美国FDA的四种加快

CDE提醒：恶意钓鱼邮件骗取药企信息！务必谨慎小心！

梅斯医学提醒：

CDE发布《中药生物效应检测研究技术指导原则（征求意见稿）》

为提高中药质量可控性，鼓励研究探索中药生物效应检测方法，建立完善符合中药特点且关联临床疗效和安全性的质量评价与控制体系，我中心组织起草了《中药生物效应检测研究技术指导原则（征求意见稿）》。